New CV Outcomes Study May Mean Big Boost For Amgen's Repatha Market
Executive Summary
The addressable patient population in the US could increase by 4.5 million if new trial is successful.
You may also be interested in...
Amid New M&A Rumors, Amarin CEO Focused On Vascepa Approval
John Thero insists company is focused on approval and launch, as interest in European rights grow.
Can Sanofi Catch Up With Amgen Now That Praluent Has CV Risk-Reduction Claim?
ODYSSEY Outcomes data added to US label for Praluent; update includes claim for reduced cardiovascular incident risk and trial data indicating an all-cause mortality benefit.
Sanofi/Regeneron Cut Praluent List Price As PBMs Look To Maintain Rebate Status Quo
The move follows a similar price cut for Amgen's competing PCSK9 inhibitor Repatha and comes as PBMs, including UnitedHealth Group's OptumRx, are looking for ways to maintain the drug rebate status quo.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports